STOCK TITAN

Pacira BioSciences director disposes of 20,136 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Pacira BioSciences, Inc. (PCRX) director Mark Froimson reported the disposition of 20,136 common shares on November 17, 2026, in Viatris’ cash tender offer at $36.50 per share, net of applicable withholding taxes and without interest. At the merger’s effective time that day, 6,405 restricted stock units were canceled and converted into a cash right based on the shares issuable and the $36.50 offer price, subject to tax withholding. Nine option positions were canceled: options with exercise prices below the offer price converted into cash rights based on the difference between those prices; options at or above the offer price were canceled for no consideration. Pacira became a wholly owned subsidiary of Viatris.

Insider Froimson Mark
Role Director
Type Security Shares Price Value
Disposition Stock Option (Right to Buy) F3 4,693 -- --
Disposition Stock Option (Right to Buy) F3 8,437 -- --
Disposition Stock Option (Right to Buy) F3 8,027 -- --
Disposition Stock Option (Right to Buy) F3 7,626 -- --
Disposition Stock Option (Right to Buy) F3 8,225 -- --
Disposition Stock Option (Right to Buy) F3 12,925 -- --
Disposition Stock Option (Right to Buy) F3 11,279 -- --
Disposition Stock Option (Right to Buy) F3 10,891 -- --
Disposition Stock Option (Right to Buy) F3 8,144 -- --
Tender Offer Common Stock F1 20,136 $36.50 $735K
Disposition Common Stock F2 6,405 $36.50 $234K
Holdings After Transaction: Stock Option (Right to Buy) — 0 options (Direct); Common Stock — 0 shares (Direct)
Holdings Before and After: Stock Option (Right to Buy), 80,247 to 0 options (Direct); Common Stock, 26,541 to 0 shares (Direct)
Footnotes (3)
  1. F1. Disposed of pursuant to the Agreement and Plan of Merger, dated as of October 8, 2026, by and among Pacira BioSciences, Inc. ("Issuer"), Viatris Inc. ("Viatris") and Peach Purchaser Sub Inc. ("Purchaser") (the "Merger Agreement"), pursuant to which Purchaser consummated a cash tender offer (the "Offer") to purchase all of the outstanding shares of Issuer's common stock (the "Shares") for $36.50 per Share, net of applicable withholding taxes and without interest (the "Offer Price"), after which Purchaser merged with and into Issuer with Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). On November 17, 2026, the effective time of the Merger (the "Effective Time"), each Share was converted into the right to receive the Offer Price.
  2. F2. Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award ("RSU") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares issuable in settlement of such RSU, multiplied by (ii) the Offer Price, subject to applicable tax withholdings.
  3. F3. Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares ("Option") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per Share under such Option, subject to applicable tax withholdings. Each Option that was outstanding immediately prior to the Effective Time which had a per Share exercise price greater than or equal to the Offer Price was cancelled at the Effective Time with no consideration payable.
Common shares disposed of 20,136 shares Disposed of in the tender offer on November 17, 2026
Offer Price $36.50 per share Cash tender offer price, net of applicable withholding taxes and without interest
Restricted stock units 6,405 shares issuable Canceled and converted into a cash right based on the Offer Price, subject to applicable tax withholding
Options with $24.34 exercise price 11,279 underlying shares Exercise price was below the $36.50 Offer Price; merger terms provided for cash consideration based on the difference
Options with $23.42 exercise price 10,891 underlying shares Exercise price was below the $36.50 Offer Price; merger terms provided for cash consideration based on the difference
cash tender offer financial
"Purchaser consummated a cash tender offer to purchase all outstanding shares"
A cash tender offer is a public proposal in which an individual or group offers to buy a set number of a company's shares directly from shareholders for a specified cash price during a limited time. It matters to investors because it gives a clear, immediate chance to sell shares at a known price — like a store offering to buy back items at a posted rate — and can affect the stock’s market price, ownership control and liquidity.
Effective Time financial
"November 17, 2026, the effective time of the Merger"
The exact clock time when a regulatory filing, approval, or corporate action formally becomes legally active; from that moment the change is binding and can be acted on. Investors care because the effective time marks when ownership, rights, trading rules, or new securities take effect — like a light switch turning on a contract or transaction — which determines when risks, benefits and market reactions begin.
Offer Price financial
"each Share was converted into the right to receive the Offer Price"
The offer price is the amount per share that a company or underwriter sets when selling new stock or bonds to investors, like the price tag on an item in a store. It matters because it determines how much investors must pay, shapes the initial market value of the security, and influences whether demand will be strong or weak — which affects early trading performance and potential returns.
restricted stock unit award financial
"each restricted stock unit award outstanding immediately prior to the Effective Time"
A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.
Merger Agreement financial
"Agreement and Plan of Merger among the Issuer, Viatris and Purchaser"
A merger agreement is a binding contract that lays out the exact terms for two companies to combine, including the price, what each side will deliver, and the conditions that must be met before the deal is completed. Investors care because it sets the timetable, payouts and risks — like a blueprint or prenup that shows whether the deal is likely to close, how ownership will change, and what could cancel or alter the payout they expect.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How were Mark Froimson’s Pacira options treated in the merger?

At the merger’s effective time on November 17, 2026, Pacira options were canceled. Options with exercise prices below the $36.50 Offer Price converted into a cash right based on the option shares multiplied by the difference between the offer price and exercise price, subject to applicable tax withholding. Options with exercise prices at or above $36.50 were canceled for no consideration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Froimson Mark

(Last)(First)(Middle)
C/O PACIRA BIOSCIENCES, INC.
2000 SIERRA POINT PARKWAY, SUITE 900

(Street)
BRISBANE CALIFORNIA 94005

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/17/2026U(1)20,136D$36.56,405D
Common Stock11/17/2026D(2)6,405D$36.50D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$38.3511/17/2026D4,693 (3)06/13/2028Common Stock4,693(3)0D
Stock Option (Right to Buy)$43.5411/17/2026D8,437 (3)06/05/2029Common Stock8,437(3)0D
Stock Option (Right to Buy)$47.6511/17/2026D8,027 (3)06/09/2030Common Stock8,027(3)0D
Stock Option (Right to Buy)$60.9611/17/2026D7,626 (3)06/09/2031Common Stock7,626(3)0D
Stock Option (Right to Buy)$59.3911/17/2026D8,225 (3)06/08/2032Common Stock8,225(3)0D
Stock Option (Right to Buy)$38.7411/17/2026D12,925 (3)06/14/2033Common Stock12,925(3)0D
Stock Option (Right to Buy)$24.3411/17/2026D11,279 (3)06/11/2035Common Stock11,279(3)0D
Stock Option (Right to Buy)$23.4211/17/2026D10,891 (3)06/10/2036Common Stock10,891(3)0D
Stock Option (Right to Buy)$44.211/17/2026D8,144 (3)06/14/2027Common Stock8,144(3)0D
Explanation of Responses:
1. Disposed of pursuant to the Agreement and Plan of Merger, dated as of October 8, 2026, by and among Pacira BioSciences, Inc. ("Issuer"), Viatris Inc. ("Viatris") and Peach Purchaser Sub Inc. ("Purchaser") (the "Merger Agreement"), pursuant to which Purchaser consummated a cash tender offer (the "Offer") to purchase all of the outstanding shares of Issuer's common stock (the "Shares") for $36.50 per Share, net of applicable withholding taxes and without interest (the "Offer Price"), after which Purchaser merged with and into Issuer with Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). On November 17, 2026, the effective time of the Merger (the "Effective Time"), each Share was converted into the right to receive the Offer Price.
2. Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award ("RSU") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares issuable in settlement of such RSU, multiplied by (ii) the Offer Price, subject to applicable tax withholdings.
3. Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares ("Option") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per Share under such Option, subject to applicable tax withholdings. Each Option that was outstanding immediately prior to the Effective Time which had a per Share exercise price greater than or equal to the Offer Price was cancelled at the Effective Time with no consideration payable.
Remarks:
/s/ Kristen Williams, Attorney-in-Fact11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading